Junctional Epidermolysis Bullosa (JEB) Cell Models for Research

Junctional epidermolysis bullosa (JEB) is a rare, inherited blistering disorder caused by mutations in genes encoding basement membrane proteins. Global incidence is estimated at 1 in 1,000,000 to 1 in 4,000,000 live births (WHO, 2023). The severe subtype, intermediate generalized JEB (formerly Herlitz JEB), has high infant mortality; approximately 40-50% of affected infants die within the first year of life due to sepsis, failure to thrive, or respiratory complications (NCI, 2022). Risk factors include consanguinity and family history. Five-year survival for severe JEB is less than 30%, whereas milder subtypes have near-normal life expectancy (NCI, 2022).

JEB is an ideal model for mechanistic studies of skin adhesion, extracellular matrix assembly, and gene therapy. Subtypes include intermediate generalized JEB (LAMA3, LAMB3, LAMC2 mutations), severe generalized JEB (same genes), and JEB with pyloric atresia (ITGB4, ITGA6 mutations). Public datasets such as ClinVar and NCBI Gene provide mutation spectra. Open questions include: how do specific mutations affect protein folding and secretion? What are the compensatory pathways in mild vs. severe phenotypes? Gene-edited cell models enable precise dissection of these mechanisms.

JEB is not typically a carcinogenic disease, but chronic inflammation and scarring can predispose to squamous cell carcinoma (SCC) in some subtypes. Key pathways involved in JEB pathogenesis and potential malignant transformation include:

1. Laminin-332 (laminin-5) signaling: Laminin-332 is a major component of anchoring filaments. Mutations in LAMA3, LAMB3, or LAMC2 lead to absent or truncated protein, causing dermal-epidermal separation.

2. Integrin α6β4 signaling: Mutations in ITGB4 or ITGA6 disrupt hemidesmosome formation, leading to severe blistering and pyloric atresia.

3. Collagen XVII (COL17A1) pathway: Defects cause non-Herlitz JEB; collagen XVII is a transmembrane protein in hemidesmosomes.

4. TGF-β and inflammatory signaling: Chronic wounds in JEB show elevated TGF-β, which may contribute to fibrosis and SCC risk.

Data from ClinVar and COSMIC (as of 2024) show the following mutation frequencies in JEB:

Note: Frequencies vary by population; LAMB3 mutations are most common in European cohorts.

Key signaling networks disrupted in JEB include:

• • Laminin-332/integrin α6β4 axis:
• • Laminin-332 binds integrin α6β4, stabilizing hemidesmosomes.
• • Loss leads to detachment and activation of stress kinases (JNK, p38).
• • TGF-β/SMAD pathway:
• • Chronic wounds increase TGF-β1, promoting fibrosis and SCC.
• • SMAD2/3 phosphorylation is elevated in JEB keratinocytes.
• • PI3K/AKT/mTOR pathway:
• • Activated in response to cell detachment (anoikis resistance).
• • May contribute to SCC development in severe JEB.
• • Wnt/β-catenin signaling:
• • Altered in JEB-associated SCC; β-catenin accumulates in nuclei.

Several cell lines and organoids model JEB. Key examples:

Organoid advantages: 3D structure mimics skin architecture, allows study of basement membrane assembly, and enables drug testing in a physiologically relevant context.

Animal models for JEB include:

• • Lamc2-/- mice: Severe blistering at birth, die within 2 weeks; mimic severe JEB.
• • Lamb3-/- mice: Die shortly after birth due to skin detachment.
• • Col17a1-/- mice: Viable with mild blistering; model non-Herlitz JEB.
• • Patient-derived xenografts (PDX): Human JEB skin grafted onto immunodeficient mice; useful for gene therapy testing.
• • Induced models: CRISPR-mediated knockout of Lama3 in mouse keratinocytes.

These models are valuable for preclinical testing of gene-corrected skin grafts and small molecules.

CRISPR/Cas9 is used to create isogenic JEB cell lines. Examples:

• • LAMB3 knockout in HaCaT keratinocytes: Models severe JEB; used to study laminin-332 assembly.
• • COL17A1 knockout in primary keratinocytes: Models non-Herlitz JEB; enables drug screening for collagen XVII restoration.
• • ITGB4 knock-in of patient-specific missense mutations: Models JEB with pyloric atresia.
• • LAMA3 knockout iPSCs: Differentiated into keratinocytes for disease modeling.

Commercially available, sequence-verified gene-edited cell models (e.g., knockout and knock-in lines) accelerate research by providing reproducible, validated tools. These models are generated using CRISPR and quality-controlled by Sanger sequencing and functional assays. They enable researchers to bypass time-consuming model generation and focus on mechanistic studies and drug discovery.

Knockout and knock-in lines validate gene function in JEB. Examples:

• • LAMB3 knockout keratinocytes: Confirm that laminin-332 is essential for hemidesmosome stability.
• • COL17A1 knockout: Demonstrate role in epidermal adhesion and wound healing.
• • ITGB4 knock-in: Assess specific missense mutations for their impact on integrin signaling.
• • CRISPR screens: Identify modifiers of JEB severity, such as genes in TGF-β pathway.

Isogenic pairs (wild-type vs. mutant) enable high-throughput drug screens. Examples:

• • LAMB3 knockout vs. isogenic control: Screen for compounds that restore laminin-332 secretion or enhance cell adhesion.
• • COL17A1 mutant lines: Test small molecules that stabilize collagen XVII folding.
• • Resistance modeling: Chronic JEB wounds often become resistant to standard therapies; gene-edited cells help identify resistance mechanisms.

CRISPR synthetic lethality screens in JEB cells identify vulnerabilities. Examples:

• • Genome-wide knockout screen in LAMB3-null cells: Identify genes whose loss is lethal only in JEB cells, revealing potential drug targets.
• • Transcriptomic profiling of isogenic lines: Discover biomarkers for disease severity.
• • Proteomic analysis: Identify secreted factors that could serve as biomarkers.